Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection
Clinical trial NCT07368803 · RECRUITING
Trial details
- NCT number
- NCT07368803
- Sponsor
- Yifan Wang
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-11
- Primary completion
- 2027-09-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.